ACADIA has two additional collaboration agreements with Allergan also.

The collaboration is targeted on the discovery of latest therapeutics for glaucoma and other ophthalmic indications and was originally founded in March 2003. The study term of the collaboration has now been prolonged by the parties for yet another year through March 2012. ACADIA has two additional collaboration agreements with Allergan also, which have resulted in current clinical applications in the regions of chronic discomfort and glaucoma. Related StoriesScientists propose that Alzheimer's disease ought to be treated separatelyEnvisia's ENV515 meets main efficacy endpoint in phase 2a glaucoma trialAllergan enters into agreement to acquire Aquesys and its XEN45 system’We are delighted to increase our longstanding scientific collaboration with Allergan, an acknowledged leader in the field of eye caution,’ said Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA. Continue reading